ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1AAPL | APPLE INC | Technology | $5.16T | 44.10% |
2LLY | ELI LILLY & CO | Healthcare | $1.34T | 11.48% |
3JNJ | JOHNSON & JOHNSON | Healthcare | $682.52B | 5.84% |
4ABBV | ABBVIE INC | Healthcare | $520.47B | 4.45% |
5MRK | MERCK & CO INC | Healthcare | $362.27B | 3.10% |
6TMO | THERMO FISHER SCIENTIFIC INC | Healthcare | $259.15B | 2.22% |
7AMGN | AMGEN INC | Healthcare | $252.64B | 2.16% |
8GILD | GILEAD SCIENCES INC | Healthcare | $208.31B | 1.78% |
9ABT | ABBOTT LABORATORIES | Healthcare | $185.75B | 1.59% |
10PFE | PFIZER INC | Healthcare | $164.33B | 1.41% |
11DHR | DANAHER CORP | Healthcare | $163.33B | 1.40% |
12VRTX | VERTEX PHARMACEUTICALS INC | Healthcare | $137.57B | 1.18% |
13BMY | BRISTOL MYERS SQUIBB CO | Healthcare | $127.39B | 1.09% |
14GLW | CORNING INC | Technology | $102.94B | 0.88% |
15REGN | REGENERON PHARMACEUTICALS INC | Healthcare | $98.40B | 0.84% |
16MRNA | MODERNA INC | Healthcare | $93.61B | 0.80% |
17TT | TRANE TECHNOLOGIES PLC | Industrials | $92.82B | 0.79% |
18EMR | EMERSON ELECTRIC CO | Industrials | $91.57B | 0.78% |
19HWM | HOWMET AEROSPACE INC | Industrials | $88.72B | 0.76% |
20NUE | NUCOR CORP | Basic Materials | $58.65B | 0.50% |
21AME | AMETEK INC | Industrials | $55.27B | 0.47% |
22IDXX | IDEXX LABORATORIES INC | Healthcare | $54.99B | 0.47% |
23TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Healthcare | $50.93B | 0.44% |
24A | AGILENT TECHNOLOGIES INC | Healthcare | $48.78B | 0.42% |
25ONC | BEONE MEDICINES LTD | Healthcare | $47.50B | 0.41% |
26WAT | WATERS CORP | Healthcare | $45.43B | 0.39% |
27ROK | ROCKWELL AUTOMATION INC | Industrials | $44.89B | 0.38% |
28RPRX | ROYALTY PHARMA PLC | Healthcare | $39.56B | 0.34% |
29RVMD | REVOLUTION MEDICINES INC | Healthcare | $38.14B | 0.33% |
30BIIB | BIOGEN INC | Healthcare | $37.03B | 0.32% |
31MTD | METTLER TOLEDO INTERNATIONAL INC | Healthcare | $34.43B | 0.29% |
32STLD | STEEL DYNAMICS INC | Basic Materials | $33.72B | 0.29% |
33ZTS | ZOETIS INC | Healthcare | $33.71B | 0.29% |
34ROIV | ROIVANT SCIENCES LTD | Healthcare | $28.98B | 0.25% |
35VLTO | VERALTO CORP | Industrials | $28.57B | 0.24% |
36INSM | INSMED INC | Healthcare | $25.90B | 0.22% |
37ATI | ATI INC | Industrials | $25.83B | 0.22% |
38UTHR | UNITED THERAPEUTICS CORP | Healthcare | $25.27B | 0.22% |
39VTRS | VIATRIS INC | Healthcare | $23.70B | 0.20% |
40HUBB | HUBBELL INC | Industrials | $23.14B | 0.20% |
41ALNY | ALNYLAM PHARMACEUTICALS INC | Healthcare | $20.98B | 0.18% |
42FTV | FORTIVE CORP | Technology | $20.20B | 0.17% |
43NBIX | NEUROCRINE BIOSCIENCES INC | Healthcare | $17.15B | 0.15% |
44JAZZ | JAZZ PHARMACEUTICALS PLC | Healthcare | $15.43B | 0.13% |
45BBIO | BRIDGEBIO PHARMA INC | Healthcare | $15.23B | 0.13% |
46CRS | CARPENTER TECHNOLOGY CORP | Industrials | $14.84B | 0.13% |
47ELAN | ELANCO ANIMAL HEALTH INC | Healthcare | $13.25B | 0.11% |
48JKHY | JACK HENRY & ASSOCIATES INC | Technology | $12.26B | 0.10% |
49SMMT | SUMMIT THERAPEUTICS INC | Healthcare | $12.06B | 0.10% |
50MLI | MUELLER INDUSTRIES INC | Industrials | $11.95B | 0.10% |
51HALO | HALOZYME THERAPEUTICS INC | Healthcare | $11.48B | 0.10% |
52TECH | BIO-TECHNE CORP | Healthcare | $11.44B | 0.10% |
53BMRN | BIOMARIN PHARMACEUTICAL INC | Healthcare | $10.98B | 0.09% |
54KYMR | KYMERA THERAPEUTICS INC | Healthcare | $10.86B | 0.09% |
55AA | ALCOA CORP | Basic Materials | $10.68B | 0.09% |
56RGEN | REPLIGEN CORP | Healthcare | $10.64B | 0.09% |
57PCVX | VAXCYTE INC | Healthcare | $10.24B | 0.09% |
58BIO | BIO-RAD LABORATORIES INC | Healthcare | $9.96B | 0.09% |
59MDGL | MADRIGAL PHARMACEUTICALS INC | Healthcare | $9.88B | 0.08% |
60SYRE | SPYRE THERAPEUTICS INC | Healthcare | $9.77B | 0.08% |
61TGTX | TG THERAPEUTICS INC | Healthcare | $9.76B | 0.08% |
62PRAX | PRAXIS PRECISION MEDICINES INC | Healthcare | $9.08B | 0.08% |
63KRYS | KRYSTAL BIOTECH INC | Healthcare | $9.06B | 0.08% |
64PTGX | PROTAGONIST THERAPEUTICS INC | Healthcare | $8.77B | 0.08% |
65CORT | CORCEPT THERAPEUTICS INC | Healthcare | $8.07B | 0.07% |
66ALKS | ALKERMES PLC | Healthcare | $7.89B | 0.07% |
67CYTK | CYTOKINETICS INC | Healthcare | $7.82B | 0.07% |
68RYTM | RHYTHM PHARMACEUTICALS INC | Healthcare | $7.62B | 0.07% |
69AXSM | AXSOME THERAPEUTICS INC | Healthcare | $7.59B | 0.06% |
70KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | Healthcare | $7.56B | 0.06% |
71AMRX | AMNEAL PHARMACEUTICALS INC | Healthcare | $7.56B | 0.06% |
72IMVT | IMMUNOVANT INC | Healthcare | $7.25B | 0.06% |
73TWST | TWIST BIOSCIENCE CORP | Healthcare | $7.16B | 0.06% |
74ORKA | ORUKA THERAPEUTICS INC | Healthcare | $7.12B | 0.06% |
75CMC | COMMERCIAL METALS CO | Basic Materials | $7.02B | 0.06% |
76KOD | KODIAK SCIENCES INC | Healthcare | $6.80B | 0.06% |
77RIOT | RIOT PLATFORMS INC | Financial Services | $6.69B | 0.06% |
78ARWR | ARROWHEAD PHARMACEUTICALS INC | Healthcare | $6.66B | 0.06% |
79LNTH | LANTHEUS HOLDINGS INC | Healthcare | $6.62B | 0.06% |
80SAIC | SCIENCE APPLICATIONS INTERNATIONAL CORP | Technology | $6.34B | 0.05% |
81LGND | LIGAND PHARMACEUTICALS INC | Healthcare | $6.33B | 0.05% |
82CGON | CG ONCOLOGY INC | Healthcare | $6.27B | 0.05% |
83MIRM | MIRUM PHARMACEUTICALS INC | Healthcare | $6.09B | 0.05% |
84ST | SENSATA TECHNOLOGIES HOLDING PLC | Technology | $5.74B | 0.05% |
85MANE | VERADERMICS INC | Healthcare | $5.71B | 0.05% |
86PTCT | PTC THERAPEUTICS INC | Healthcare | $5.29B | 0.05% |
87SRRK | SCHOLAR ROCK HOLDING CORP | Healthcare | $5.27B | 0.05% |
88DNTH | DIANTHUS THERAPEUTICS INC | Healthcare | $5.21B | 0.04% |
89COGT | COGENT BIOSCIENCES INC | Healthcare | $5.07B | 0.04% |
90EWTX | EDGEWISE THERAPEUTICS INC | Healthcare | $5.02B | 0.04% |
91TVTX | TRAVERE THERAPEUTICS INC | Healthcare | $4.95B | 0.04% |
92ADPT | ADAPTIVE BIOTECHNOLOGIES CORP | Healthcare | $4.77B | 0.04% |
93IONS | IONIS PHARMACEUTICALS INC | Healthcare | $4.55B | 0.04% |
94DFTX | DEFINIUM THERAPEUTICS INC | Healthcare | $4.52B | 0.04% |
95FELE | FRANKLIN ELECTRIC CO INC | Industrials | $4.31B | 0.04% |
96ITRI | ITRON INC | Technology | $4.23B | 0.04% |
97TNGX | TANGO THERAPEUTICS INC | Healthcare | $4.21B | 0.04% |
98CRSP | CRISPR THERAPEUTICS AG | Healthcare | $4.13B | 0.04% |
99OLED | UNIVERSAL DISPLAY CORP | Technology | $4.05B | 0.03% |
100XENE | XENON PHARMACEUTICALS INC | Healthcare | $4.03B | 0.03% |
101BDC | BELDEN INC | Technology | $4.00B | 0.03% |
102RLAY | RELAY THERAPEUTICS INC | Healthcare | $3.99B | 0.03% |
103AMLX | AMYLYX PHARMACEUTICALS INC | Healthcare | $3.84B | 0.03% |
104ABCL | ABCELLERA BIOLOGICS INC | Healthcare | $3.80B | 0.03% |
105TARS | TARSUS PHARMACEUTICALS INC | Healthcare | $3.79B | 0.03% |
106IRON | DISC MEDICINE INC | Healthcare | $3.79B | 0.03% |
107OGN | ORGANON & CO | Healthcare | $3.65B | 0.03% |
108NATL | NCR ATLEOS CORP | Technology | $3.57B | 0.03% |
109ELVN | ENLIVEN THERAPEUTICS INC | Healthcare | $3.56B | 0.03% |
110IOVA | IOVANCE BIOTHERAPEUTICS INC | Healthcare | $3.53B | 0.03% |
111VKTX | VIKING THERAPEUTICS INC | Healthcare | $3.52B | 0.03% |
112CENX | CENTURY ALUMINUM CO | Basic Materials | $3.52B | 0.03% |
113ARQT | ARCUTIS BIOTHERAPEUTICS INC | Healthcare | $3.48B | 0.03% |
114DYN | DYNE THERAPEUTICS INC | Healthcare | $3.19B | 0.03% |
115MGRC | MCGRATH RENTCORP | Industrials | $3.17B | 0.03% |
116ACAD | ACADIA PHARMACEUTICALS INC | Healthcare | $3.14B | 0.03% |
117BHC | BAUSCH HEALTH COMPANIES INC | Healthcare | $3.09B | 0.03% |
118IDYA | IDEAYA BIOSCIENCES INC | Healthcare | $3.04B | 0.03% |
119XERS | XERIS BIOPHARMA HOLDINGS INC | Healthcare | $3.04B | 0.03% |
120DNLI | DENALI THERAPEUTICS INC | Healthcare | $3.03B | 0.03% |
121ADMA | ADMA BIOLOGICS INC | Healthcare | $2.94B | 0.03% |
122VCEL | VERICEL CORP | Healthcare | $2.93B | 0.03% |
123WOR | WORTHINGTON ENTERPRISES INC | Industrials | $2.87B | 0.02% |
124XNCR | XENCOR INC | Healthcare | $2.86B | 0.02% |
125MBX | MBX BIOSCIENCES INC | Healthcare | $2.71B | 0.02% |
126RCUS | ARCUS BIOSCIENCES INC | Healthcare | $2.56B | 0.02% |
127BEAM | BEAM THERAPEUTICS INC | Healthcare | $2.49B | 0.02% |
128NEOG | NEOGEN CORP | Healthcare | $2.44B | 0.02% |
129SDGR | SCHRODINGER INC | Healthcare | $2.32B | 0.02% |
130NTCT | NETSCOUT SYSTEMS INC | Technology | $2.31B | 0.02% |
131PRGO | PERRIGO CO PLC | Healthcare | $2.25B | 0.02% |
132CLDX | CELLDEX THERAPEUTICS INC | Healthcare | $2.24B | 0.02% |
133IMNM | IMMUNOME INC | Healthcare | $2.21B | 0.02% |
134AUPH | AURINIA PHARMACEUTICALS INC | Healthcare | $2.17B | 0.02% |
135PBH | PRESTIGE CONSUMER HEALTHCARE INC | Healthcare | $2.15B | 0.02% |
136BHVN | BIOHAVEN LTD | Healthcare | $2.13B | 0.02% |
137SUPN1 | SUPERNUS PHARMACEUTICALS INC | Healthcare | $2.11B | 0.02% |
138VERA | VERA THERAPEUTICS INC | Healthcare | $2.10B | 0.02% |
139VIR | VIR BIOTECHNOLOGY INC | Healthcare | $2.08B | 0.02% |
140TRAX | FIRST TRACKS BIOTHERAPEUTICS INC | Healthcare | $2.05B | 0.02% |
141MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | Healthcare | $2.00B | 0.02% |
142SEPN | SEPTERNA INC | Healthcare | $1.99B | 0.02% |
143HRMY | HARMONY BIOSCIENCES HOLDINGS INC | Healthcare | $1.98B | 0.02% |
144BCRX | BIOCRYST PHARMACEUTICALS INC | Healthcare | $1.98B | 0.02% |
145WS | WORTHINGTON STEEL INC | Basic Materials | $1.97B | 0.02% |
146MAZE | MAZE THERAPEUTICS INC | Healthcare | $1.97B | 0.02% |
147TRVI | TREVI THERAPEUTICS INC | Healthcare | $1.94B | 0.02% |
148AGIO | AGIOS PHARMACEUTICALS INC | Healthcare | $1.90B | 0.02% |
149ZBIO | ZENAS BIOPHARMA INC | Healthcare | $1.87B | 0.02% |
150COAG | HEMAB THERAPEUTICS HOLDINGS INC | Healthcare | $1.84B | 0.02% |
151DBD | DIEBOLD NIXDORF INC | Technology | $1.84B | 0.02% |
152ZYME | ZYMEWORKS INC | Healthcare | $1.83B | 0.02% |
153KALU | KAISER ALUMINUM CORP | Basic Materials | $1.81B | 0.02% |
154ETON | ETON PHARMACEUTICALS INC | Healthcare | $1.77B | 0.02% |
155QURE | UNIQURE NV | Healthcare | $1.73B | 0.01% |
156SRPT | SAREPTA THERAPEUTICS INC | Healthcare | $1.72B | 0.01% |
157KLRA | KAILERA THERAPEUTICS INC | Healthcare | $1.72B | 0.01% |
158STOK | STOKE THERAPEUTICS INC | Healthcare | $1.71B | 0.01% |
159NRIX | NURIX THERAPEUTICS INC | Healthcare | $1.70B | 0.01% |
160RARE | ULTRAGENYX PHARMACEUTICAL INC | Healthcare | $1.66B | 0.01% |
161SLS | SELLAS LIFE SCIENCES GROUP INC | Healthcare | $1.62B | 0.01% |
162ANIP | ANI PHARMACEUTICALS INC | Healthcare | $1.62B | 0.01% |
163GENB | GENERATE BIOMEDICINES INC | Healthcare | $1.61B | 0.01% |
164IMCR | IMMUNOCORE HOLDINGS PLC | Healthcare | $1.57B | 0.01% |
165RAPP | RAPPORT THERAPEUTICS INC | Healthcare | $1.53B | 0.01% |
166NTLA | INTELLIA THERAPEUTICS INC | Healthcare | $1.48B | 0.01% |
167PCRX | PACIRA BIOSCIENCES INC | Healthcare | $1.46B | 0.01% |
168NVAX | NOVAVAX INC | Healthcare | $1.45B | 0.01% |
169PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.44B | 0.01% |
170ANAB | ANAPTYSBIO INC | Healthcare | $1.43B | 0.01% |
171KRSA | KORSANA BIOSCIENCES INC | Healthcare | $1.42B | 0.01% |
172GPCR | STRUCTURE THERAPEUTICS INC | Healthcare | $1.42B | 0.01% |
173LQDT | LIQUIDITY SERVICES INC | Consumer Cyclical | $1.41B | 0.01% |
174OCUL | OCULAR THERAPEUTIX INC | Healthcare | $1.38B | 0.01% |
175LBRX | LB PHARMACEUTICALS INC | Healthcare | $1.37B | 0.01% |
176MLYS | MINERALYS THERAPEUTICS INC | Healthcare | $1.37B | 0.01% |
177TYRA | TYRA BIOSCIENCES INC | Healthcare | $1.37B | 0.01% |
178DMRA | DAMORA THERAPEUTICS INC | Healthcare | $1.36B | 0.01% |
179AVLN | AVALYN PHARMA INC | Healthcare | $1.36B | 0.01% |
180INVA | INNOVIVA INC | Healthcare | $1.35B | 0.01% |
181OMER | OMEROS CORP | Healthcare | $1.30B | 0.01% |
182URGN | UROGEN PHARMA LTD | Healthcare | $1.29B | 0.01% |
183CMPS | COMPASS PATHWAYS PLC | Healthcare | $1.29B | 0.01% |
184INBX | INHIBRX BIOSCIENCES INC | Healthcare | $1.29B | 0.01% |
185NKTR | NEKTAR THERAPEUTICS | Healthcare | $1.27B | 0.01% |
186AMPH | AMPHASTAR PHARMACEUTICALS INC | Healthcare | $1.23B | 0.01% |
187ANRO | ALTO NEUROSCIENCE INC | Healthcare | $1.23B | 0.01% |
188VOR | VOR BIOPHARMA INC | Healthcare | $1.19B | 0.01% |
189MLTX | MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | $1.10B | 0.01% |
190SPTX | SEAPORT THERAPEUTICS INC | Healthcare | $1.08B | 0.01% |
191VSTM | VERASTEM INC | Healthcare | $1.06B | 0.01% |
192HROW | HARROW INC | Healthcare | $1.06B | 0.01% |
193CYRX | CRYOPORT INC | Industrials | $1.02B | 0.01% |
194JBIO | JADE BIOSCIENCES INC | Healthcare | $1.01B | 0.01% |
195ODTX | ODYSSEY THERAPEUTICS INC | Healthcare | $966M | 0.01% |
196ROCK | GIBRALTAR INDUSTRIES INC | Industrials | $918M | 0.01% |
197SXC | SUNCOKE ENERGY INC | Basic Materials | $913M | 0.01% |
198AKTS | AKTIS ONCOLOGY INC | Healthcare | $906M | 0.01% |
199CRVS | CORVUS PHARMACEUTICALS INC | Healthcare | $896M | 0.01% |
200NX | QUANEX BUILDING PRODUCTS CORP | Industrials | $886M | 0.01% |
201ORIC | ORIC PHARMACEUTICALS INC | Healthcare | $881M | 0.01% |
202NWPX | NWPX INFRASTRUCTURE INC | Industrials | $879M | 0.01% |
203RIGL | RIGEL PHARMACEUTICALS INC | Healthcare | $860M | 0.01% |
204SNDX | SYNDAX PHARMACEUTICALS INC | Healthcare | $859M | 0.01% |
205MGTX | MEIRAGTX HOLDINGS PLC | Healthcare | $844M | 0.01% |
206GLUE | MONTE ROSA THERAPEUTICS INC | Healthcare | $796M | 0.01% |
207ALMS | ALUMIS INC | Healthcare | $793M | 0.01% |
208RGR | STURM RUGER & CO INC | Industrials | $790M | 0.01% |
209SLDB | SOLID BIOSCIENCES INC | Healthcare | $781M | 0.01% |
210COLL | COLLEGIUM PHARMACEUTICAL INC | Healthcare | $775M | 0.01% |
211AURA | AURA BIOSCIENCES INC | Healthcare | $740M | 0.01% |
212QDEL | QUIDELORTHO CORP | Healthcare | $729M | 0.01% |
213MTUS | METALLUS INC | Basic Materials | $717M | 0.01% |
214JANX | JANUX THERAPEUTICS INC | Healthcare | $703M | 0.01% |
215NVCT | NUVECTIS PHARMA INC | Healthcare | $696M | 0.01% |
216QUIT | ACHIEVE LIFE SCIENCES INC | Healthcare | $692M | 0.01% |
217KURA | KURA ONCOLOGY INC | Healthcare | $683M | 0.01% |
218SGMT | SAGIMET BIOSCIENCES INC | Healthcare | $679M | 0.01% |
219DSGN | DESIGN THERAPEUTICS INC | Healthcare | $678M | 0.01% |
220AVBP | ARRIVENT BIOPHARMA INC | Healthcare | $676M | 0.01% |
221BCAX | BICARA THERAPEUTICS INC | Healthcare | $671M | 0.01% |
222FDMT | 4D MOLECULAR THERAPEUTICS INC | Healthcare | $669M | 0.01% |
223ZVRA | ZEVRA THERAPEUTICS INC | Healthcare | $664M | 0.01% |
224DNA | GINKGO BIOWORKS HOLDINGS INC | Healthcare | $663M | 0.01% |
225CGEM | CULLINAN THERAPEUTICS INC | Healthcare | $662M | 0.01% |
226OLMA | OLEMA PHARMACEUTICALS INC | Healthcare | $659M | 0.01% |
227CADL | CANDEL THERAPEUTICS INC | Healthcare | $642M | 0.01% |
228CLYM | CLIMB BIO INC | Healthcare | $639M | 0.01% |
229SRZN | SURROZEN INC | Healthcare | $604M | 0.01% |
230MATW | MATTHEWS INTERNATIONAL CORP | Industrials | $590M | 0.01% |
231IMMX | IMMIX BIOPHARMA INC | Healthcare | $577M | 0.00% |
232IIIN | INSTEEL INDUSTRIES INC | Industrials | $545M | 0.00% |
233MYGN | MYRIAD GENETICS INC | Healthcare | $545M | 0.00% |
234CBIO | CRESCENT BIOPHARMA INC | Healthcare | $534M | 0.00% |
235RGNX | REGENXBIO INC | Healthcare | $531M | 0.00% |
236TKNO | ALPHA TEKNOVA INC | Healthcare | $522M | 0.00% |
237PHAT | PHATHOM PHARMACEUTICALS INC | Healthcare | $506M | 0.00% |
238DMAC | DIAMEDICA THERAPEUTICS INC | Healthcare | $503M | 0.00% |
239NGNE | NEUROGENE INC | Healthcare | $495M | 0.00% |
240MNPR | MONOPAR THERAPEUTICS | Healthcare | $488M | 0.00% |
241EOLS | EVOLUS INC | Healthcare | $475M | 0.00% |
242ARVN | ARVINAS INC | Healthcare | $450M | 0.00% |
243AVTX | AVALO THERAPEUTICS INC | Healthcare | $445M | 0.00% |
244PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $423M | 0.00% |
245TECX | TECTONIC THERAPEUTIC INC | Healthcare | $420M | 0.00% |
246PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $418M | 0.00% |
247ASMB | ASSEMBLY BIOSCIENCES INC | Healthcare | $411M | 0.00% |
248LYEL | LYELL IMMUNOPHARMA INC | Healthcare | $385M | 0.00% |
249CTNM | CONTINEUM THERAPEUTICS INC | Healthcare | $384M | 0.00% |
250FENC | FENNEC PHARMACEUTICALS INC | Healthcare | $382M | 0.00% |
251PEPG | PEPGEN INC | Healthcare | $349M | 0.00% |
252TWI | TITAN INTERNATIONAL INC | Industrials | $333M | 0.00% |
253MPLT | MAPLIGHT THERAPEUTICS INC | Healthcare | $328M | 0.00% |
254EIKN | EIKON THERAPEUTICS INC | Healthcare | $327M | 0.00% |
255ENTA | ENANTA PHARMACEUTICALS INC | Healthcare | $326M | 0.00% |
256BNTC | BENITEC BIOPHARMA INC | Healthcare | $317M | 0.00% |
257KYTX | KYVERNA THERAPEUTICS INC | Healthcare | $311M | 0.00% |
258AGEN | AGENUS INC | Healthcare | $311M | 0.00% |
259TTRX | TURN THERAPEUTICS INC | Healthcare | $310M | 0.00% |
260EBS | EMERGENT BIOSOLUTIONS INC | Healthcare | $303M | 0.00% |
261IRHO | IRON HORSE ACQUISITION II CORP | Financial Services | $296M | 0.00% |
262EVMN | EVOMMUNE INC | Healthcare | $291M | 0.00% |
263UCFI | CN HEALTHY FOOD TECH GROUP CORP | Consumer Defensive | $288M | 0.00% |
264FRD | FRIEDMAN INDUSTRIES INC | Basic Materials | $275M | 0.00% |
265QTTB | Q32 BIO INC | Healthcare | $264M | 0.00% |
266BIOA | BIOAGE LABS INC | Healthcare | $260M | 0.00% |
267ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $243M | 0.00% |
268LFCR | LIFECORE BIOMEDICAL INC | Healthcare | $243M | 0.00% |
269USNA | USANA HEALTH SCIENCES INC | Consumer Defensive | $235M | 0.00% |
270IMMR | IMMERSION CORP | Technology | $231M | 0.00% |
271DTIL | PRECISION BIOSCIENCES INC | Healthcare | $225M | 0.00% |
272GLSI | GREENWICH LIFESCIENCES INC | Healthcare | $224M | 0.00% |
273TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $202M | 0.00% |
274TG | TREDEGAR CORP | Industrials | $198M | 0.00% |
275KROS | KEROS THERAPEUTICS INC | Healthcare | $198M | 0.00% |
276KRRO | KORRO BIO INC | Healthcare | $196M | 0.00% |
277RNAC | CARTESIAN THERAPEUTICS INC | Healthcare | $194M | 0.00% |
278ACOG | ALPHA COGNITION INC | Healthcare | $186M | 0.00% |
279NATR | NATURES SUNSHINE PRODUCTS INC | Consumer Defensive | $178M | 0.00% |
280BOOM | DMC GLOBAL INC | Energy | $164M | 0.00% |
281STRO | SUTRO BIOPHARMA INC | Healthcare | $159M | 0.00% |
282RNA | ATRIUM THERAPEUTICS INC | Healthcare | $128M | 0.00% |
283CUE | CUE BIOPHARMA INC | Healthcare | $127M | 0.00% |
284SPRB | SPRUCE BIOSCIENCES INC | Healthcare | $123M | 0.00% |
285ACNT | ASCENT INDUSTRIES CO | Basic Materials | $121M | 0.00% |
286IMUX | IMMUNIC INC | Healthcare | $106M | 0.00% |
287KEQU | KEWAUNEE SCIENTIFIC CORP | Consumer Cyclical | $104M | 0.00% |
288CPIX | CUMBERLAND PHARMACEUTICALS INC | Healthcare | $99M | 0.00% |
289FVN | FUTURE VISION II ACQUISITION CORP | Financial Services | $98M | 0.00% |
290ICCC | IMMUCELL CORP | Healthcare | $93M | 0.00% |
291LGL | LGL GROUP INC | Technology | $88M | 0.00% |
292RLYB | RALLYBIO CORP | Healthcare | $84M | 0.00% |
293VTVT | VTV THERAPEUTICS INC | Healthcare | $83M | 0.00% |
294CPHC | CANTERBURY PARK HOLDING CORP | Consumer Cyclical | $81M | 0.00% |
295ATRA | ATARA BIOTHERAPEUTICS INC | Healthcare | $81M | 0.00% |
296WTG | WINTERGREEN ACQUISITION CORP | Financial Services | $79M | 0.00% |
297FTLF | FITLIFE BRANDS INC | Consumer Defensive | $78M | 0.00% |
298ALIS | CALISA ACQUISITION CORP | Financial Services | $71M | 0.00% |
299GOSS | GOSSAMER BIO INC | Healthcare | $69M | 0.00% |
300LFVN | LIFEVANTAGE CORP | Consumer Defensive | $64M | 0.00% |
301XLO | XILIO THERAPEUTICS INC | Healthcare | $58M | 0.00% |
302YARW | YARROW BIOSCIENCE INC | Healthcare | $52M | 0.00% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $11.69T. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
2 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
No more than 25% of total assets may be invested in the securities of any one issuer.
The fund will not concentrate: no more than 25% of total assets in any one industry (excluding government securities and cash items).
Days required to liquidate the largest position at 20% of one day's dollar volume.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T063725 rates=20261113T063725
Measured on the 2026-11 formation date across 302 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 6.6% | -16.2% |
| 3 yearsp.a. | 14.0% | -21.4% |
| 5 yearsp.a. | 8.4% | -6.7% |
| 10 yearsp.a. | 12.4% | -8.5% |
| Since inceptionp.a. | 7.5% | -4.9% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 6.4% | -18.4% |
| 2025 | 7.9% | -26.7% |
| 2024 | 25.5% | -6.7% |
| 2023 | 13.3% | -24.5% |
| 2022 | -12.3% | 38.9% |
| 2021 | 20.0% | 5.4% |
| 2020 | 19.9% | -39.7% |
| 2019 | 29.3% | -0.5% |
| 2018 | 0.9% | 15.2% |
| 2017 | 18.3% | -3.2% |
| 2016 | 8.1% | -10.4% |
| 2015 | 0.8% | 12.4% |
| 2014 | 13.3% | 3.6% |
| 2013 | 34.8% | -20.4% |
| 2012 | 17.1% | -9.6% |
| 2011 | 8.6% | 34.1% |
| 2010 | 7.6% | -27.0% |
| 2009 | 14.0% | -28.0% |
| 2008 | -25.3% | 78.4% |
| 2007 | 11.3% | 20.6% |
| 2006 | 17.6% | -0.9% |
| 2005 | 4.3% | -0.2% |
| 2004 | 8.1% | -6.9% |
| 2003 | 23.4% | -27.3% |
| 2002 | -25.4% | 50.2% |
| 2001 | -11.6% | 10.9% |
| 2000 | -14.9% | 42.7% |
| 1999 | 20.5% | -66.6% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Low Volatility Industry-Neutral Factor ETF tracks a rules-based model that ranks liquid U.S. common stocks, industry-neutralized within Fama-French industries, each month by a Low Volatility signal and holds the top decile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
Share of long-leg capital by market cap × book-to-market, using terciles of the 3,140-name universe at November 2026. Rows: Large ≥ $5.3B, Small < $832M. Columns: Value ≥ 0.62, Growth < 0.33 B/M. The dot marks the capital-weighted centroid of the book — 99% toward Large, 94% toward Growth. +3% unclassified (34 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 302 names now. Hypothetical holdings — descriptive, not P&L.